Biomarin Pharmaceutical (BMRN) Share-based Compensation (2009 - 2026)
Biomarin Pharmaceutical's (BMRN) quarterly Share-based Compensation came in at $43.5 million in Q1 2026, up 12.07% YoY from $38.8 million in Q1 2025, and down 7.36% on a QoQ basis from $46.9 million in Q4 2025.
Biomarin Pharmaceutical (BMRN) Share-based Compensation (2009 - 2026) Analysis & Trends
Biomarin Pharmaceutical (BMRN) has 18 years of Share-based Compensation data on file, last reported at $43.5 million in Q1 2026.
- Quarterly Share-based Compensation rose 12.07% year-over-year to $43.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $186.1 million (up 220.34% YoY) and the FY2025 annual result came in at $181.4 million, up 133.9% from the prior year.
- Share-based Compensation eased to $43.5 million in Q1 2026, from $46.9 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $105.2 million in Q3 2022 to a low of -$95.3 million in Q4 2022.
- A 5-year average of $25.5 million and a median of $38.8 million in 2025 frame the typical range for Share-based Compensation.
- The widest YoY moves for Share-based Compensation: up 1746.53% in 2022, down 162.35% in 2022.
- Tracing BMRN's Share-based Compensation over 5 years: stood at -$95.3 million in 2022, then jumped by 104.11% to $3.9 million in 2023, then advanced by 25.23% to $4.9 million in 2024, then soared by 855.65% to $46.9 million in 2025, then declined by 7.36% to $43.5 million in 2026.
- The last three Share-based Compensation figures came in at $43.5 million (Q1 2026), $46.9 million (Q4 2025), and $49.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Biomarin Pharmaceutical | 13.04 Bn | 12.16 Bn | 786.91 Mn | 75.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 75.69 Mn |
| Jun 30, 2026 | 75.69 Mn |
| Mar 31, 2026 | 43.46 Mn |
| Mar 31, 2026 | 43.46 Mn |
| Dec 31, 2025 | 46.91 Mn |
| Dec 31, 2025 | 46.91 Mn |
| Sep 30, 2025 | 49.27 Mn |
| Sep 30, 2025 | 49.27 Mn |
| Jun 30, 2025 | 46.45 Mn |
| Jun 30, 2025 | 46.45 Mn |
| Mar 31, 2025 | 38.78 Mn |
| Mar 31, 2025 | 38.78 Mn |
| Dec 31, 2024 | 4.91 Mn |
| Dec 31, 2024 | 4.91 Mn |
| Sep 30, 2024 | 5.91 Mn |
| Sep 30, 2024 | 5.91 Mn |
| Jun 30, 2024 | 8.49 Mn |
| Jun 30, 2024 | 8.49 Mn |
| Mar 31, 2024 | 58.25 Mn |
| Mar 31, 2024 | 58.25 Mn |